Conference Correspondent
News, views, and coverage of important topics and discussions from oncology conferences and events.
Compared with myChoice HRD, percentage of loss of heterozygosity score identifies a significantly smaller proportion of BRCA-mutated tumors. Read More ›
Phase II OVARIO study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab. Read More ›
In patients with platinum-sensitive recurrent epithelial ovarian cancer, olaparib monotherapy did not improve survival over standard-of-care chemotherapy. Read More ›
After discontinuing treatment with a PARP inhibitor, waiting longer to initiate subsequent therapy was associated with better tolerance to post–PARP inhibitor therapy, with no negative impact on progression-free survival. Read More ›
Patient-reported outcomes from nearly 2000 women with gynecologic cancers revealed that black women have more suffering, less support, and worse health than white women. Read More ›
Progression-free survival was significantly increased with olaparib plus bevacizumab as maintenance therapy overall and across all important subgroups. Read More ›
Pomalidomide, Cyclophosphamide, and Dexamethasone (POMCIDEX) in Relapsed/Refractory Multiple Myeloma
Pragmatic setting administration of the all-oral combination of pomalidomide plus cyclophosphamide/dexamethasone (POMCIDEX) is a manageable, effective treatment option for patients with relapsed/refractory multiple myeloma. Read More ›
Based on early results of a dose-escalation study, teclistamab demonstrated an overall response rate of 67% at the highest dose, as well as reasonable tolerability with low incidence of high-grade cytokine release syndrome in patients with advanced relapsed/refractory multiple myeloma. Read More ›
Isatuximab plus carfilzomib/dexamethasone (IKEMA study) shows promising efficacy and tolerable safety in prolonging progression-free survival compared with carfilzomib/dexamethasone alone in the treatment of patients with RRMM. Read More ›
Efficacy and toxicity outcome measures with daratumumab added to carfilzomib/dexamethasone were consistent across subgroups within the CANDOR trial, regardless of lenalidomide- or bortezomib-refractory status or number of previous treatments. Read More ›